

***EVI1* overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of *EVI1* to the *MSI2* locus at 17q22**

An De Weer,¹ Frank Speleman,¹ Barbara Cauwelier,² Nadine Van Roy,¹ Nurten Yigit,¹ Bruno Verhasselt,³ Barbara De Moerloose,⁴ Yves Benoit,⁴ Lucien Noens,⁵ Dominik Selleslag,² Eric Lippert,⁶ Stephanie Struski,⁷ Christian Bastard,⁸ Anne De Paepe,¹ Peter Vandenberghe,⁹ Anne Hagemeijer,⁹ Nicole Dastugue,¹⁰ and Bruce Poppe¹ on behalf of the Groupe Français de Cytogénétique Hématologique (GFCH)

¹Centre for Medical Genetics Gent (CMGG), Ghent University Hospital, Ghent, Belgium; ²Department of Hematology, Hospital St-Jan, Brugge, Belgium; ³Department of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, Ghent, Belgium; ⁴Department of Pediatric Hemato-Oncology, Ghent University Hospital, Ghent, Belgium; ⁵Department of Hematology, Ghent University Hospital, Ghent, Belgium; ⁶Laboratoire d'Hématologie, Groupe Hospitalier Haut-Leveque - CHU de Bordeaux, Bordeaux, France; ⁷Laboratoire d'Hématologie, Hôpital de Hautepierre, Strasbourg, France; ⁸Genetic laboratory and EMI 9906, Centre Henri Becquerel, Rouen, France; ⁹Centre for Human Genetics, University of Leuven, Leuven, Belgium and ¹⁰Laboratoire d'Hématologie, Hôpital Purpan, Toulouse, France

ABSTRACT

Chromosomal translocations involving the *EVI1* locus are a recurrent finding in myeloid leukemia and are associated with poor prognosis. In this study, we performed a detailed molecular characterization of the recurrent translocation t(3;17)(q26;q22) in 13 hematologic malignancies. The *EVI1* gene locus was rearranged in all 13 patients and was associated with *EVI1* overexpression. In 9 out of 13 patients, the 17q breakpoints clustered in a 250 kb region on band 17q22 encompassing the *MSI2* (*musashi homologue 2*) gene. Expression analyses failed to demonstrate ectopic *MSI2* expression or the presence of an *MSI2/EVI1* fusion gene. In conclusion, we show for the first time that the t(3;17) is indeed a recurrent chromosomal aberration in myeloid malignancies. In keeping with findings in other recurrent 3q26 rearrangements, overexpression of the *EVI1* gene appears to be the major contributor to leukemogenesis in patients with a t(3;17).

Key words: *EVI1*, *MSI2*, myeloid malignancies, t(3;17), FISH.

Citation: De Weer A, Speleman F, Cauwelier B, Van Roy N, Yigit N, Verhasselt B, De Moerloose B, Benoit Y, Noens L, Selleslag D, Lippert E, Struski S, Bastard C, De Paepe A, Vandenberghe P, Hagemeijer A, Dastugue N, and Poppe B on behalf of the Groupe Français de Cytogénétique Hématologique (GFCH). *EVI1* overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of *EVI1* to the *MSI2* locus at 17q22. *Haematologica* 2008; 93:1903-1907. doi: 10.3324/haematol.13192

©2008 Ferrata Storti Foundation. This is an open-access paper.

Introduction

The Ecotropic Viral Integration site 1 (*EVI1*) gene is located at chromosome band 3q26.2 and was identified as a proto-oncogene by retroviral integration assays in mice.¹ Rearrangements of the *EVI1* locus are found in acute myeloid leukemias (AML), myelodysplastic syndromes (MDS) and chronic myeloid leukemias (CML). *EVI1* gene rearrangements account for approximately 5% of cytogenetic abnormalities in these disease entities.² Patients with an *EVI1* rearrangement have distinct clinical features, such as marked hyperplasia with dysplasia of the megakaryocytes³ and, in some cases, hyperthrombocytosis.⁴

These 3q26 chromosomal aberrations confer an adverse prognosis and contribute to ectopic expression of either full length or truncated *EVI1* transcripts, or to the formation of *EVI1* fusion genes.² Common recurrent rearrangements affecting the 3q26 locus include the inv(3)(q21q26) and the translocation t(3;3)(q21;q26), in which *EVI1* overexpression is caused by juxtaposition of the *EVI1* gene to enhancer elements of the Ribophorin (RPN) gene at 3q21 (5). *EVI1* activation in the translocations t(3;12)(q26;p13) and t(3;21)(q26;q22) is due to generation of the fusion genes *ETV6/EVI1* and *RUNX1/EVI1* respectively.^{6,7}

In addition to these well-characterized rearrangements, the *EVI1* locus is also involved in rare 3q26 aberrations such

Funding: ADW is the recipient of a BOF grant (Bijzonder Onderzoeksfonds UGent, grant n. 01D28905). BP, PV and BV are senior clinical investigators of FWO-Vlaanderen. This study was supported by the FWO-Vlaanderen, grant n. G.0106.05 and by GOA-UGent, grant n. 12051203.

Manuscript received April 7, 2008. Revised version arrived on July 16, 2008. Manuscript accepted August 4, 2008.

Correspondence: Bruce Poppe, Centre for Medical Genetics Gent (CMGG), Ghent University Hospital 185, De Pintelaan B-9000, Ghent, Belgium.

E-mail: bruce.poppe@ugent.be

as the t(3;17)(q26;q22),⁸ the t(2;3)(p21~22;q26)^{9,10} and the t(3;6)(q26;q25).¹¹ For these *EVI1* rearrangements, the true recurrent nature and the partner chromosomes involved, have not been analyzed in detail. Therefore, we performed an in depth characterization of the 17q breakpoints in 13 hematologic malignancies with a t(3;17).

Design and Methods

Patients and cell lines

In this multicenter retrospective study 13 leukemias were included according to the following criteria; presence of a hematologic malignancy with a t(3;17) and 3q26 rearrangement. Karyotyping of diagnostic samples was performed according to standard procedures. Several myeloid leukemia cell lines (K562 and U937) and *EVI1* rearranged cell lines (Kasumi-3 and UCSD-AML1) were included as positive controls for *EVI1* overexpression.¹²⁻¹⁵ The study was approved by the ethics committee of the Ghent University Hospital (2003/273). Patients' characteristics and karyotypes are described in Table 1.

Fluorescence in situ hybridization

Dual-color fluorescence *in situ* hybridization (FISH) with a dedicated *EVI1* probe set (RP11-362K14, RP11-

82C9 and RP11-694D5) was performed on fixed nuclei and/or metaphases of patients and cell lines.⁸ To characterize the 17q breakpoints, eight different 17q BAC/PAC probes over a region of 34.3 Mb on 17q were selected from the UCSC (<http://genome.ucsc.edu>) or Ensembl (<http://ensembl.org>) databases. The 17q and *EVI1* probes were all obtained from the Sanger Wellcome Trust Institute, Hinxton, Cambridge (United Kingdom). Position of the probes used and location of translocation breakpoints is described in Figures 1 A–B.

Real-time quantitative RT-PCR

Total RNA was extracted from total bone marrow samples or bone marrow leukocytes from 9 of 13 t(3;17) samples, from 4 myeloid cell lines, from bone marrow of 3 patients without a hematologic disorder and from 2 stem cell (CD34⁺) fractions, using the miRNeasy kit (Qiagen, Belgium) according to the manufacturer's recommendations. The cell lines and CD34⁺ cells served as positive controls for the study of *EVI1* expression as well as for *MSI2* expression. cDNA was prepared from 2 µg of total RNA with the iScript cDNA Synthesis Kit (Bio-Rad, Belgium) according to the manufacturer's descriptions.

Real-time quantitative RT-PCR (qRT-PCR) for the *EVI1* (exon 1b-2), *cEVI1* (exon 8-9, primers located at the 3' end of the *EVI1* gene to detect possible 5' tran-

Table 1 Patients' characteristics, diagnosis, sex, age at diagnosis, G-banded karyotype.

Case	Diagnosis [†]	Percentage of blasts in t(3;17) sample	Age at diagnosis (years)	Sex [‡]	Karyotype	<i>EVI1</i>	Treatment	Survival
1	MDS	8	66	F	46,XX,t(3;17)(q26;q22)[12]	-	Supportive transfusions	7 years
2	CML-BC	48	25	M	46,XY,t(3;17)(q26;q22),t(9;22)(q34;q11.2)[18]	**	AraC	10 months
3	CML-BC	45	69	M	46,XY,t(3;17)(q26;q22),t(9;22)(q34;q11.2), t(12;13)(p12;q13)[16]/47,sl,+8[2]	**	Hydrea	4 months
4	AML	22	6	M	45,XY,t(3;17)(q26;q22),-7[18]	+	AraC/VP16/M	6 months
5	MDS	7	58	M	47,XY,+3,del(3)(q25q27),t(3;17)(q26;q12), del(6)(p23),-20,-21,+2mar[8]	-	AraC/VP16/D	15 months
6	CML-BC	59	65	M	46,XY,t(9;22)(q34;q11.2)[2]/46,sl,t(3;17)(q26;q22)[18]	+	Hydrea/6-M	4 months
7	AML	29	64	F	46,XX,t(3;17)(q26;q22),t(9;22)(q34;q11.2)[5]/46,XX[7]	+	**	**
8	AML	15	73	F	45,XX,t(3;17)(q26;q22),-7[6]	-	6-T/G	alive (2 years) [¶]
9	AML	29	66	F	46,XX,t(3;17)(q26;q22)[10]	**	AraC/D	**
10	CML-BC	45	57	M	50,XY,t(3;9;22;17)(q26;q34;q11;q22), +8,+der(9)t(3;9;22;17), +10,+12,del(16)(q23)[15]	+	AraC/D	9 months
11	MDS	15	42	M	46,XY,t(3;17)(q26;q22)[21]/46,sl,der(16)t(1;16)(q12;q12)[2]	-	allo SC	alive (3 years) [¶]
12	AML	23	25	M	45,XY,t(3;17)(q26;q22),-7[2]/46,sl,+12[10]	+	AraC/D	7 months
13	AML	47	63	M	44,XY,t(2;3;17)(p21;q26;q22), der(7)t(7;15)(p14;q15),der(10)t(10;16)(q26;q12-q13),-15,-16[25]	**	AraC/I/CCNU/Hydrea	15 months

[†]MDS: myelodysplastic syndrome; CML: chronic myeloid leukemia; CML-BC: CML in blast crisis and AML: acute myeloid leukemia (according to FAB classification)

[‡]M: male and F: female. AraC: 1-β-D-arabinofuranosylcytosine; D: daunorubicin, VP16: etoposide; M: mitoxantrone; I: idarubicin; H: hydroxyurea; allo SC: allogeneic stem cell transplantation, 6-T = 6-thioguanine, G = gemtuzumab ozogamicin, 6-M = 6-mercaptopurine and CCNU = lomustine ¶ Survival time at publication ** No data available +Positive for *EVI1* overexpression with qRT-PCR. - Negative for *EVI1* overexpression with qRT-PCR.




Figure 1. Schematic overview of the location of the 17q and 3q probes and breakpoints. (A). Physical map of the 3q26.2 probes used. The locations of the *EVI1* breakpoints in the 13 t(3;17) patients are indicated by shaded boxes. (B). Location of the 17q22 breakpoint for 9 out of 13 patients. Vertical arrows indicate location of the breakpoints within the *MSI2* gene.

script variants),¹⁶ *MDS1/EVI1* (data not shown) and *MSI2* (primer pairs for exon 3 and 10) transcripts was performed as previously described.^{8,17} For normalization three housekeeping genes (*RPL13A*, *YWHAZ* and *HPRT1*) were selected in view of their stability in bone marrow samples as analyzed using the Genom software.¹⁷ The *EVI1* overexpressing cell line Kasumi-3 carrying a t(3;7)(q26;q22) translocation¹² was used as a positive control.

RT-PCR

To investigate the possibility of *MSI2/EVI1* fusion gene formation, RT-PCR was performed. Based on the known *EVI1* breakpoint position in fusion genes and the location of the *MSI2* 17q breakpoints, primers for the second exon of *EVI1* and the second exon of *MSI2* were selected. For PCR analysis, the following touch-down program was used: an initial denaturation step at 94°C for 2 min, 12 cycles of 20 sec at 94°C, 15 sec at the initial annealing temperature (*T_a*) 62°C (*T_a*-1°C for each cycle), 1 min at 72°C followed by 24 cycles of 40 sec at 94°C, 40 sec at 50°C, 30 sec at 72°C and a final extension step of 4 min at 72°C.

Results and Discussion

FISH analysis demonstrated a rearrangement of the *EVI1* locus in all samples. For 9 out of 13 leukemic samples, the 3q26 breakpoint was located 5' (telomeric) of the *EVI1* gene which is in keeping with previous observations of 3q26 translocation breakpoint positions.⁹ In 3 out of 13 samples, the *EVI1* breakpoint was located 3' (centromeric) of the *EVI1* gene and in case 5 the *EVI1* breakpoint was located within the region corresponding to the RP11-82C9 probe and could thus be located either 5', 3' or within the *EVI1* gene (Figure 1A).

In 9 of 13 patients the 17q breakpoint clustered in a 250 kb region on 17q22 harboring the *MSI2* gene (Figure 1B). For the remaining 3 cases, unique breakpoints were detected in BAC clones RP11-386F9 (patient #5, 17q11.2), RP11-1094H24 (patient #3, 17q21.33) and in the PAC clone RP5-1171I10 (patient #6, 17q22), respectively (data not shown). For patient #13, the 17q breakpoint overlapping clone could not be determined.

MSI2 plays a role in post-transcriptional gene regulation and in maintaining stem cell status,¹⁸ and involvement of *MSI2* in myeloid leukemias has previously been reported in 2 CML patients, one of which carried a *MSI2/HOXA9* fusion gene.¹⁹ In our patient series however, no *MSI2/EVI1* fusion gene could be detected in RT-PCR analysis. Given the opposite orientation of *MSI2* and *EVI1* and the lack of karyotypic evidence for complex rearrangements, this result was indeed anticipated.²⁰ Further study of a possible *MSI2/EVI1* fusion transcript was complicated by limited availability of patient sample. *MSI2* rearrangements have also been linked to CML and myeloproliferative disorder disease progression.^{19,21,22} Interestingly, 2 out of 9 patients with a *MSI2* breakpoint were CML-BC patients.

Frequently observed secondary karyotypic changes in CML include +8, i(17q), +19 and +Ph, but in some occasions recurrent translocations and 3q26 rearrangements are reported.²³ We postulate that the t(3;17) involving *MSI2* is associated with CML as a secondary aberration and could serve as a progression marker.

Real-time quantitative PCR with *EVI1* and *cEVI1* primers indicated that 5 out of 9 patients displayed ectopic *EVI1* expression (data not shown). In the remaining 4 patients, no ectopic *EVI1* expression could be detected. In a previous study, we showed that the majority of hematologic malignancies displaying a

rearrangement in the vicinity of *EVI1* show ectopic *EVI1* expression.⁸ Therefore, we hypothesize that in these 4 patients *EVI1* expression could not be detected because of the low blast counts in these samples. Overexpression of the *EVI1* oncogene conveys a poor prognosis in AML and CML-BC.²⁴ In our cohort, patients without detectable *EVI1* overexpression had prolonged survival compared to the patients with *EVI1* overexpression (Table 1). This enhanced prognosis could in part be explained by the absence of a high blast count which is indicative for an early stage of the disease. Therefore the patient's blast count might have to be taken into account when addressing prognosis.

The exact cause of *EVI1* overexpression is not known, but in the *inv(3)(q21q26)* and the *t(3;3)(q21;q26)* *EVI1* is juxtaposed to the enhancer elements of the Ribophorin gene on chromosome band 3q21.⁵ Possibly, *EVI1* overexpression in *t(3;17)* leukemias is driven by enhancer elements located in the vicinity of the *MSI2* locus.

We found no significant differences in *MSI2* expression between *MSI2* rearranged and *MSI2* non-rearranged *t(3;13)* hematologic malignancies (*data not shown*). Expression of *MSI2* in patients with a 17q breakpoint in *MSI2* is not straightforward. Due to the translocation, a part of the *MSI2* gene is separated from its promoter. Therefore, we postulate that the observed expression is due to residual expression from the normal allele.

No *MSI2/EVI1* fusion gene could be detected, and no significant *MSI2* expression differences were found between *MSI2* rearranged and *MSI2* non-rearranged patients. Therefore, we have no evidence of a trans-

forming role of *MSI2*. Given the expression of *MSI2* in CD34⁺ cells (*data not shown*) it is feasible that the gene is located in a region with open chromatin within the genome. As these regions are more susceptible to double strand DNA breaks, this could lead to increased vulnerability of the *MSI2* locus in chromosomal aberrations. Rearrangement and consecutive overexpression of *EVI1* seem to be the main contributor to tumorigenesis in *t(3;17)* patients.

In conclusion, we confirm the *t(3;17)* as a recurrent chromosomal aberration in myeloid malignancies, consistently involving *EVI1*. We found that a distinct subgroup (9 out of 13) shares a recurrent 17q breakpoint region implicating the *MSI2* gene, and postulate that overexpression of the *EVI1* gene is the major contributor to leukemogenesis in patients with a *t(3;17)*.

Authorship and Disclosures

ADW: performed FISH and expression analysis, drafted the manuscript; FS: helped drafting the manuscript; BC: helped with the RT-PCR; NVR: helped drafting the manuscript; NY: helped with FISH experiments; BV: helped with drafting the manuscript; BDM, YB, LN, DS, EL, SS, CB, PV, AH, ND: supplied patient samples; ADP: helped drafting the manuscript; BP: helped drafting the manuscript.

This text presents research results of the Belgian Program of Interuniversity Poles of Attraction initiated by the Belgian State, Prime Minister's Office, Science Policy Programming. The scientific responsibility is assumed by the authors.

References

- Perkins AS, Fishel R, Jenkins NA, Copeland NG. Evi-1, a murine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding protein. *Mol Cell Biol* 1991;11:2665-74.
- Buonamici S, Chakraborty S, Senyuk V, Nucifora G. The role of EVI1 in normal and leukemic cells. *Blood Cells Mol Dis* 2003;31:206-12.
- Lopingco MC, Perkins AS. Molecular analysis of Evi1, a zinc finger oncogene involved in myeloid leukemia. *Curr Top Microbiol Immunol* 1996; 211:211-22.
- Levy ER, Parganas E, Morishita K, Fichelson S, James L, Oscier D, et al. DNA rearrangements proximal to the EVI1 locus associated with the 3q21q26 syndrome. *Blood* 1994;83: 1348-54.
- Hirai H. The transcription factor Evi-1. *Int J Biochem Cell Biol* 1999;31: 1367-71.
- Bohlander SK. Fusion genes in leukemia: an emerging network. *Cytogenet Cell Genet* 2000;91:52-6.
- Nucifora G, Rowley JD. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. *Blood* 1995;86:1-14.
- Poppe B, Dastugue N, Vandesompele J, Cauwelier B, De Smet B, Yigit N, et al. EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements. *Genes Chromosomes Cancer* 2006; 45:349-56.
- Stevens-Kroef M, Poppe B, van Zelder-Bhola S, van den Berg E, van der Blij-Philipsen M, Geurts van Kessel A, et al. Translocation *t(2;3)(p15-23;q26-27)* in myeloid malignancies: report of 21 new cases, clinical, cytogenetic and molecular genetic features. *Leukemia* 2004;18: 1108-14.
- Trubia M, Albano F, Cavazzini F, Cambrin GR, Quarta G, Fabbiano F, et al. Characterization of a recurrent translocation *t(2;3)(p15-22;q26)* occurring in acute myeloid leukaemia. *Leukemia* 2006;20:48-54.
- Charrin C, Belhabri A, Treille-Ritouet D, Theuil G, Magaud JP, Fiere D, et al. Structural rearrangements of chromosome 3 in 57 patients with acute myeloid leukemia: clinical, hematological and cytogenetic features. *Hematol J* 2002;3:21-31.
- Asou H, Suzukawa K, Kita K, Nakase K, Ueda H, Morishita K, et al. Establishment of an undifferentiated leukemia cell line (Kasumi-3) with *t(3;7)(q27;q22)* and activation of the EVI1 gene. *Japan J Cancer Res* 1996; 87:269-74.
- Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. *Blood* 1975;45:321-34.
- Oval J, Jones OW, Montoya M, Taetle R. Characterization of a factor-dependent acute leukemia cell line with translocation (3;3)(q21;q26). *Blood* 1990;76:1369-74.
- Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). *Int J Cancer* 1976; 17: 565-77.
- Vinatzer U, Mannhalter C, Mitterbauer M, Gruener H, Greinix H, Schmidt HH, et al. Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia. *Genes Chromosomes Cancer* 2003; 36:80-9.
- Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-

- time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol* 2002;3:1-11.
18. Siddall NA, McLaughlin EA, Mariner NL, Hime GR. The RNA-binding protein Musashi is required intrinsically to maintain stem cell identity. *Proc Natl Acad Sci USA* 2006;103:8402-7.
 19. Barbouti A, Hoglund M, Johansson B, Lassen C, Nilsson PG, Hagemeijer A, et al. A novel gene, *MSI2*, encoding a putative RNA-binding protein is recurrently rearranged at disease progression of chronic myeloid leukemia and forms a fusion gene with *HOXA9* as a result of the cryptic t(7;17)(p15;q23). *Cancer Res* 2003; 63:1202-6.
 20. Van Limbergen H, Poppe B, Janssens A, De Bock R, De Paepe A, Noens L, et al. Molecular cytogenetic analysis of 10;11 rearrangements in acute myeloid leukemia. *Leukemia* 2002; 16:344-51.
 21. Mugneret F, Solary E, Favre B, Caillot D, Sidaner I, Guy H. New case of t(3;17)(q26;q22) as an additional change in a Philadelphia-positive chronic myelogenous leukemia in acceleration. *Cancer Genet Cytogenet* 1992;60:90-2.
 22. Mecucci C, Michaux JL, Broeckaert-Van Orshoven A, Symann M, Boogaerts M, Kulling G, et al. Translocation t(3;17)(q26;q22): a marker of acute disease in myeloproliferative disorders? *Cancer Genet Cytogenet* 1984;12:111-9.
 23. Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. *N Engl J Med* 2003;349:1451-64.
 24. Lugthart S, Drunen EV, Norden YV, Hoven AV, Erpelinck CA, Valk PJ, et al. High *EVI1* levels predict adverse outcome in acute myeloid leukemia: prevalence of *EVI1* overexpression and chromosome 3q26 abnormalities underestimated. *Blood* 2008; 111:4329-37.

©Ferrata Storti Foundation